NABP Pharmacy Accreditation FAQ — Your Questions Answered

What is NABP and what pharmacy accreditation programs does it administer?

The National Association of Boards of Pharmacy (NABP) is a nonprofit organization that assists state boards of pharmacy in protecting public health by providing programs and services to the regulatory community. NABP is not a standards development organization in the same vein as URAC or The Joint Commission — it functions primarily as a regulatory enforcement and verification body on behalf of state licensing authorities.

NABP administers four primary accreditation and verification programs relevant to pharmacies and drug distributors:

• Drug Distributor Accreditation (DDA) — formerly VAWD. For wholesale prescription drug distributors. Required by statute in four states. As of early 2026, 757 facilities hold active DDA accreditation.
• Specialty Pharmacy Accreditation — for dispensing pharmacies serving patients with complex chronic conditions. Required by Optum Rx for Specialty Pharmacy Network participation. Approximately 80 locations hold this accreditation nationally.
• Digital Pharmacy Accreditation — formerly VIPPS. For internet and mail-order pharmacies. 87 primary business entities hold this accreditation as of 2025.
• Healthcare Merchant Accreditation — required by Google, Bing, Visa, and Mastercard before permitting pharmacy advertising or card payment processing. In a recent annual cycle, NABP processed 228 new accreditations and 328 reaccreditations.

Source: NABP 2024–2025 Annual Report

What is NABP Drug Distributor Accreditation (DDA) and who needs it?

NABP Drug Distributor Accreditation — formerly called VAWD (Verified-Accredited Wholesale Distributors) — verifies that wholesale prescription drug distributors comply with federal law, state regulations, Good Distribution Practices, and Drug Supply Chain Security Act (DSCSA) requirements. Indiana, Maryland, North Dakota, and Wyoming require DDA by statute as a prerequisite for wholesale distribution licenses. Ohio is increasingly integrating DDA into core licensure requirements.

As of early 2026, 757 wholesale drug distribution facilities hold active DDA accreditation — up from 743 in the prior annual reporting period, which included 60 newly awarded accreditations. Source: NABP Accredited Drug Distributors Directory, 2026

What is the difference between VAWD and DDA?

VAWD and DDA are the same program — NABP renamed VAWD (Verified-Accredited Wholesale Distributors) to DDA (Drug Distributor Accreditation) to better reflect the program's scope and scope of eligible applicants. The accreditation criteria, two-phase inspection process, and underlying standards are substantively unchanged. The fee structure was revised effective December 18, 2024. If you encounter either term in state regulations or PBM contracts, they refer to the same NABP program.

What is Digital Pharmacy Accreditation (formerly VIPPS) and who needs it?

NABP Digital Pharmacy Accreditation — formerly VIPPS (Verified Internet Pharmacy Practice Sites) — is the accreditation program for internet-based and mail-order pharmacies that dispense prescriptions to patients online. As of 2025, 87 primary business entities hold this accreditation. The scale of the unaccredited online pharmacy market underscores why this credential matters: 95% to 96% of websites selling prescription drugs online operate illegally, according to NABP's Rogue Rx Activity Report. Between 2017 and 2022, 19,013 illegal online pharmacies dispensed an estimated 416 million prescriptions to US patients.

Sources: NABP Rogue Rx Activity Report; IQVIA Institute, 2023

What is the .Pharmacy domain verification program?

The .pharmacy top-level domain is controlled by NABP as a trust indicator for legitimate online pharmacies. To use a .pharmacy domain, a pharmacy must obtain NABP verification of legal operation. The domain itself is purchased through a third-party registrar at approximately $1,000 per year. The .pharmacy domain is separate from Healthcare Merchant Accreditation but complementary — pharmacies seeking both digital advertising capability and a trust-signaling domain often pursue both simultaneously.

What types of organizations can apply for NABP DDA?

NABP DDA eligibility extends well beyond traditional wholesale distributors. Eligible organization types include: wholesale drug distributors; Third-Party Logistics Providers (3PLs) that take physical possession of prescription drugs; virtual manufacturers holding drug application rights but using contract manufacturing; Section 503B outsourcing compounding facilities; reverse distributors handling expired drug destruction; and import/export entities. Each nontraditional entity type has specific eligibility pathways and documentation requirements not addressed in NABP's standard applicant guidance. IHS confirms eligibility and maps the applicable standards before you invest resources in the application process.

Are compounding pharmacies eligible for NABP DDA or specialty pharmacy accreditation?

Section 503B outsourcing facilities — facilities that compound sterile medications for office use without patient-specific prescriptions — are explicitly eligible for NABP DDA. Traditional 503A compounding pharmacies (patient-specific prescriptions) have specific pathways depending on whether they also engage in wholesale distribution activity. All compounding facilities subject to NABP review must comply with revised USP Chapters 795 (nonsterile) and 797 (sterile), which became compendially applicable in November 2023. These revisions require designation of a specific "designated person" for USP compounding oversight — 21% of nonsterile and 13% of sterile facilities failed to make this designation in NABP inspections. Source: NABP Verified Pharmacy Program Data, 2024

Do California pharmacies need additional compliance beyond NABP accreditation?

Yes. California AB 1503, effective July 1, 2026, requires all out-of-state nonresident pharmacies shipping prescriptions into California to designate a Pharmacist-in-Charge who holds an active California pharmacist license. This applies to national specialty pharmacies, mail-order pharmacies, and any out-of-state pharmacy filling California prescriptions — regardless of NABP accreditation status. NABP accreditation does not substitute for California PIC licensure. Source: Buchanan Ingersoll & Rooney

Does North Carolina law affect NABP accreditation requirements for PBM networks?

North Carolina HB 163 (2025–2026 legislative session), if enacted, would mandate that PBMs recognize NABP, URAC, or ACHC accreditation for specialty pharmacy network participation and prohibit PBMs from requiring PBM-owned proprietary accreditations. If passed, this legislation would materially expand the strategic value of NABP specialty pharmacy accreditation for independent pharmacies seeking forced network entry in North Carolina. Source: NC General Assembly, HB 163

What are the steps to get NABP Drug Distributor Accreditation (DDA)?

The NABP DDA process has six major steps: (1) Submit application via NABP's e-Profile system and engage a consultant for concurrent gap analysis; (2) NABP issues a Policy and Procedure (P&P) assessment tool — the consultant authors or revises all SOP manuals; (3) Submit P&P documentation for NABP desk review; (4) Iterative revision and resubmission until written protocols satisfy NABP's reviewer; (5) Mock survey by consultant — simulated facility tour, process review, HR file audit, staff interviews; (6) Phase 1 Supply Chain Inspection (SCI) — announced, on-site NABP visit; followed by Phase 2 DDA application processing; (7) Post-survey corrective action plan for any cited deficiencies; (8) Three-year accreditation awarded. Annual compliance reviews in years two and three.

What is the Supply Chain Inspection (SCI) and how does it differ from DDA?

The Supply Chain Inspection is Phase 1 of the DDA process — a mandatory physical on-site inspection that must be passed before the DDA accreditation application is processed. SCI costs $7,900 (application $2,200 + inspection $4,300 + eligibility $1,400). SCI covers facility conditions, storage and handling protocols, temperature and humidity monitoring continuity, DSCSA documentation, DEA controlled substance records, and carrier vetting procedures. DDA (Phase 2) is the formal accreditation, costing an additional $3,720 (application $3,280 + Year 1 maintenance $440). The two-phase structure means a deficiency identified in SCI must be remediated before the DDA clock starts — making pre-inspection preparation the highest-leverage investment in the process.

How long does the NABP DDA accreditation process take from application to award?

The NABP accreditation process typically takes 6 to 9 months from initial consulting engagement to final accreditation award. Factors that shorten the timeline: mature existing SOPs, current DSCSA systems, and organized HR files. Factors that extend it: documentation gaps requiring SOP authoring from scratch, multi-facility complexity, or a corrective action cycle following the on-site inspection. The three-year accreditation term requires annual compliance reviews in years two and three with $440 maintenance fees.

Can a consultant represent an applicant during the NABP application process?

Consultants assist extensively throughout the NABP process — but the pharmacy or distributor submits all materials directly via its own NABP e-Profile account. IHS prepares all documentation, authors SOPs, coaches staff for surveyor interviews, executes mock surveys, and manages corrective action cycles. IHS does not submit applications on behalf of clients or interact directly with NABP surveyors during the official inspection — the client's staff interfaces with NABP directly. This is an important distinction: the accreditation is awarded to your organization, not your consultant.

What documentation is required for the NABP DDA application?

NABP DDA documentation requirements span eight standard sections: ACC.A (general qualifications, business location, financial management transparency); ACC.B and ACC.E (licensure and compliance — continuous scope-of-practice monitoring, mandatory reporting of disciplinary actions, criminal convictions, civil settlements); ACC.C and ACC.D (facility requirements, disaster and emergency recovery plans, organizational structure, personnel qualification vetting); ACC.F (drug procurement and distribution — source verification, controlled substance security, storage condition mapping, inventory management, quarantine procedures); ACC.H (comprehensive SOP manuals); DSCSA documentation (electronic track-and-trace at individual package level); DEA records (biennial inventory counts, perpetual Schedule II inventory); PHY.B (sanitation logs, designated person for compounding under USP 795/797).

How much does NABP DDA accreditation cost in 2025?

The total NABP fee for the three-year DDA cycle is $12,500 effective December 18, 2024. Phase 1 (SCI): $7,900. Phase 2 (DDA application + Year 1 maintenance): $3,720. Year 2 maintenance: $440. Year 3 maintenance: $440. Consulting fees for DDA preparation with IHS are additional: $19,000–$29,000 for small distributors, $29,000–$49,000 or more for mid-to-large enterprises. Source: LighthouseAI, December 2024

What changed with NABP DDA pricing in December 2024?

Effective December 18, 2024, NABP restructured the DDA fee schedule. Key changes: Phase 1 application fee increased $1,200 (from $1,000 to $2,200); Phase 1 inspection fee decreased $700 (from $5,000 to $4,300); Phase 1 eligibility fee increased $400 (from $1,000 to $1,400); Phase 2 application fee increased $1,780 (from $1,500 to $3,280); Phase 2 Year 1 maintenance fee decreased $560 (from $1,000 to $440). Net effect: total three-year cost increased by $1,000. The restructuring shifts more cost to the application phase and reduces ongoing maintenance burden. Source: LighthouseAI

What are the total costs of NABP accreditation including consulting?

No NABP consultant publicly publishes pricing — making total cost visibility essentially nonexistent in the market. IHS provides this transparency: NABP DDA fees total $12,500 over three years. IHS consulting engagements for DDA preparation range from $19,000 to $29,000 for small distributors and $29,000 to $49,000 or more for mid-to-large distribution enterprises. Total first-year investment: approximately $31,500 to $61,500 or more. For specialty pharmacy accreditation fees, NABP's current schedule is available at nabp.pharmacy — contact IHS for a scoped engagement estimate based on your organizational profile. [consulting cost range — industry data reference]

What are the most common reasons NABP specialty pharmacy applications fail?

The five most common NABP specialty pharmacy survey deficiencies, ranked by frequency: (1) Incomplete patient profiles (PHY.F) — missing diagnosis codes, full medication histories including OTC and herbal supplements, allergies, and therapeutic goals; (2) Narrow DUR systems (PHY.E) — automated systems configured to check only the first two medications in a patient profile rather than cross-referencing against all current health conditions; (3) Missing patient education documentation (PHY.F) — no written proof that a pharmacist verbally educated the patient on safe handling and vaccine recommendations; (4) Welcome kit tracking failures (PHY.F) — no verifiable documentation that required informational welcome kits were sent and received; (5) HR competency assessment gaps (ACC.D) — personnel files lacking initial training documentation or ongoing competency evaluations.

What are the most common NABP DDA survey deficiencies?

For wholesale distributors, the most common DDA deficiencies are: (1) Poorly authored SOPs (ACC.H) — outdated, internally conflicting, or staff-inaccessible SOP manuals; (2) Temperature and humidity monitoring gaps (ACC.F) — missing continuous 24/7/365 electronic warehouse monitoring or absent initial thermal mapping; (3) Carrier vetting failures (ACC.F) — inability to document that contracted shipping carriers conduct mandatory criminal background checks and random toxicology screenings on employees handling prescription assets; (4) Missing designated person for compounding (PHY.B) — 21% of nonsterile and 13% of sterile facilities failed this requirement; (5) Incomplete sanitation logs (PHY.B) — missing daily cleaning records for days when nonsterile compounding occurred. Source: NABP Verified Pharmacy Program Data, 2024

What happens if a pharmacy fails the NABP on-site survey?

A failed NABP survey produces a post-survey letter citing specific operational and documentary deficiencies under the applicable standard sections. The pharmacy must author a corrective action plan for each cited finding, implement the corrective actions, and demonstrate to NABP that each deficiency has been remediated. NABP does not publish pass or denial rates. The corrective action cycle adds weeks to months to the accreditation timeline depending on the nature and number of deficiencies. IHS provides post-survey corrective action plan authoring and remediation management to resolve findings as quickly as possible. Organizations that complete the IHS mock survey before the official NABP visit resolve the majority of potential deficiencies before the surveyor arrives.

What DSCSA documentation must a wholesale distributor provide during NABP review?

DSCSA requires electronic, interoperable track-and-trace documentation at the individual prescription drug package level. For NABP DDA review, distributors must demonstrate: serialized product identification for all prescription packages handled; electronic Transaction Information (TI), Transaction History (TH), and Transaction Statement (TS) documentation for every product exchange; quarantine and investigation procedures for suspect and illegitimate products; and systems for responding to trading partner verification requests. DSCSA full interoperable enforcement is phased in, with ongoing escalation expected. NABP treats DSCSA compliance as a core ACC.F requirement — not a supplemental or future compliance item.

How does NABP specialty pharmacy accreditation compare to URAC specialty pharmacy accreditation?

NABP and URAC represent different accreditation philosophies built for different organizational needs. NABP operates as a regulatory enforcement body — its specialty pharmacy standards center on drug supply chain integrity, licensure verification, dispensing accuracy, and operational compliance with state and federal law. URAC's specialty pharmacy accreditation emphasizes clinical quality management, patient outcomes measurement, care coordination, and health plan integration.

In PBM network terms: Optum Rx requires NABP Specialty Pharmacy Accreditation for its Specialty Pharmacy Network. Other major PBMs accept NABP, URAC, or ACHC for various network tiers. 750 specialty pharmacy locations hold dual accreditation. For a full side-by-side analysis — including cost, timeline, standards scope, and which to pursue first — see our NABP vs. URAC comparison page.

Sources: PharmaTimes; Pharmacy Times

Which PBMs or payers require or prefer NABP vs. URAC accreditation?

Optum Rx specifically requires NABP Specialty Pharmacy Accreditation for its Specialty Pharmacy Network — this is a stated contractual requirement, not a preference. Other major PBM network requirements vary by contract tier and must be verified against your specific agreements. North Carolina HB 163 (2025–2026 session), if enacted, would require PBMs to accept NABP, URAC, or ACHC accreditation for network entry. IHS reviews your specific PBM contracts as part of every accreditation strategy engagement to identify which accreditation satisfies each network requirement. Source: NABP blog

Can a pharmacy hold both NABP and URAC accreditation simultaneously?

Yes — and for pharmacies with diversified PBM contracts, dual accreditation is the right strategy. 750 specialty pharmacy locations currently maintain multiple accreditations simultaneously. NABP and URAC standards overlap in several operational areas, which means a well-structured dual-accreditation engagement uses shared documentation rather than creating entirely separate compliance systems. IHS is the only consulting firm with active expertise across both NABP and URAC — we advise on optimal documentation architecture and sequencing for pharmacies pursuing both programs.

Source: Access Market Intelligence, 2025